Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 4:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 16,848 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Respiratory Tract Disease Clear all
Completed Phase 1 Interventional

PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer

NCT01723800
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
PI3K inhibitor BKM120, pemetrexed disodium, carboplatin, laboratory biomarker analysis, pharmacological study, quality-of-life assessment
Drug · Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Sep 20, 2016 · Synced Oct 14, 2026, 4:03 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis

NCT04594707
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
PRM-151 (Zinpentraxin Alfa)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Not listed
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
40
States / cities
Birmingham, Alabama • Sacramento, California • San Diego, California + 37 more
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 14, 2026, 4:03 AM EDT
Withdrawn Phase 1 Interventional

A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer

NCT06229392
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Triple Negative
Interventions
Fluzone Quadrivalent
Biological
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 14, 2026, 4:03 AM EDT
Terminated Phase 2 Interventional Results available

The Effect of Intravenous Lipids on Lung Function in Acute Respiratory Distress Syndrome (ARDS)

NCT01096771
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
ClinOleic 20%, Intralipid 20%
Drug
Lead sponsor
Methodist Research Institute, Indianapolis
Other
Eligibility
18 Years to 90 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 26, 2014 · Synced Oct 14, 2026, 4:03 AM EDT
Completed Phase 3 Interventional Results available

A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-027)

NCT03449134
View directory record Official record
Conditions
Chronic Cough
Interventions
Placebo, Gefapixant
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
27
States / cities
Litchfield Park, Arizona • Scottsdale, Arizona • La Mesa, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2021 · Synced Oct 14, 2026, 4:03 AM EDT
Completed Phase 2 Interventional Results available

B-lines Lung Ultrasound Guided ED Management of Acute Heart Failure Pilot Trial

NCT03136198
View directory record Official record
Conditions
Heart Failure, Heart Failure Acute, Acute Cardiac Pulmonary Edema, Acute Cardiac Failure
Interventions
LUS-guided strategy-of-care, Usual Care, Intravenous Loop Diuretic, Vasodilator, Non invasive Ventilation (NIV)
Other · Drug · Device
Lead sponsor
Indiana University
Other
Eligibility
21 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
6
States / cities
Indianapolis, Indiana • Detroit, Michigan • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 14, 2026, 4:03 AM EDT
Completed Not applicable Interventional

UNITE Study (UMN-SW) for COVID-19

NCT04854798
View directory record Official record
Conditions
Covid19, Cytokine Storm, Inflammation
Interventions
Splenic Ultrasound
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Burnsville, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 14, 2026, 4:03 AM EDT
Completed No phase listed Observational

EMPOWER-PULM (PULMonary Outcomes in Older Adults Empowered With Movement to Prevent Obesity and Weight Regain)

NCT03621098
View directory record Official record
Conditions
Obesity, Pulmonary Disease, Dyspnea
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
65 Years to 85 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 6, 2019 · Synced Oct 14, 2026, 4:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Renal Impairment Affects the Pharmacokinetics of PF-07817883.

NCT06586216
View directory record Official record
Conditions
COVID-19
Interventions
PF-07817883
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 90 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
3
States / cities
Miami, Florida • Tampa, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 14, 2026, 4:03 AM EDT
Active, not recruiting Phase 3 Interventional

eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

NCT02767804
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
X-396 (ensartinib), crizotinib
Drug
Lead sponsor
Xcovery Holdings, Inc.
Industry
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
4
States / cities
Tampa, Florida • Athens, Georgia • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 14, 2026, 4:03 AM EDT
Recruiting Phase 1 Interventional

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer

NCT06225804
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
ABSK112
Drug
Lead sponsor
Abbisko Therapeutics Co, Ltd
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 14, 2026, 4:03 AM EDT
Not yet recruiting Phase 2 Interventional

Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung Cancer

NCT07720167
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Cemiplimab, Carboplatin + Pemetrexed/Paclitaxel, Cisplatin
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 14, 2026, 4:03 AM EDT
Recruiting Not applicable Interventional

Magnetic Apnea Prevention(MAGNAP) Device to Treat Obstructive Sleep Apnea:First-In-Human Study of Feasibility and Safety

NCT02431507
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Magnap
Device
Lead sponsor
Michael Harrison
Other
Eligibility
21 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 14, 2026, 4:03 AM EDT
Recruiting Phase 3 Interventional

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

NCT07369011
View directory record Official record
Conditions
Sleep Apnea, Obstructive, Obesity, Overweight
Interventions
Eloralintide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
23
States / cities
Cullman, Alabama • Long Beach, California • Los Alamitos, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 14, 2026, 4:03 AM EDT
Recruiting Phase 1 Interventional

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

NCT07090499
View directory record Official record
Conditions
Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer, Carcinoma, Non Small Cell Lung, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Cancer
Interventions
PF-08046876, Pembrolizumab, Cisplatin, Carboplatin
Drug · Combination Product
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
21
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 14, 2026, 4:03 AM EDT
Not listed No phase listed Observational

Adherence and Outcome of Upper Airway Stimulation (UAS) for OSA International Registry

NCT02907398
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Inspire therapy, No intervention
Device · Other
Lead sponsor
Inspire Medical Systems, Inc.
Industry
Eligibility
Not listed
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
53
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2025 · Synced Oct 14, 2026, 4:03 AM EDT
Completed Not applicable Interventional Results available

Safety Study of Quickclot for Bleeding Control After Adenotonsillectomy

NCT01863563
View directory record Official record
Conditions
Sleep Apnea, Obstructive
Interventions
QuickClot
Device
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
2 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Oct 14, 2026, 4:03 AM EDT
Completed Phase 1 Interventional

Drug Interaction Study Between Inhaled Beclomethasone and Protease Inhibitors in Healthy Volunteers

NCT00936793
View directory record Official record
Conditions
HIV, Asthma
Interventions
Darunavir, Ritonavir, Beclomethasone Dipropionate HFA
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 60 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 14, 2026, 4:03 AM EDT
Terminated Phase 2 Interventional Results available

Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus

NCT02093221
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
180 mg/kg Alpha1-PI, 90 mg/kg Alpha1-PI, Placebo
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
6 Years to 35 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
36
States / cities
Tucson, Arizona • Los Angeles, California • Orange, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 14, 2026, 4:03 AM EDT
Completed Phase 1 Interventional

MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).

NCT02088112
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Gefitinib, MEDI4736
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 130 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
3
States / cities
Tampa, Florida • Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 14, 2026, 4:03 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

End of Life Treatment Preferences of Latino Medicare Beneficiaries With Cancer

NCT01389830
View directory record Official record
Conditions
Advanced Cancers
Interventions
Telephone Survey
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 18, 2019 · Synced Oct 14, 2026, 4:03 AM EDT
Withdrawn No phase listed Observational

Pilot Study: Cardiovascular Events in High Risk Orthopedic Surgical Patients

NCT01809730
View directory record Official record
Conditions
Coronary Artery Disease, Cerebral Vascular Disease, Peripheral Artery Disease, Renal Insufficiency, Diabetes, COPD, Hypertension, Active Smoker, Cancer, CHF, Prior DVT/PE
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Oct 14, 2026, 4:03 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

NCT07148128
View directory record Official record
Conditions
Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma, Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer, Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer, Advanced Solid Tumors, Advanced or Metastatic KRAS-mutant Tumor
Interventions
WEF-001
Drug
Lead sponsor
Auricula Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Dallas, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 14, 2026, 4:03 AM EDT
Active, not recruiting No phase listed Observational

CHaractErizing CFTR Modulated Changes in Sweat Chloride and Their Association With Clinical Outcomes

NCT03350828
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Nicole Hamblett
Other
Eligibility
4 Months and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
52
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2025 · Synced Oct 14, 2026, 4:03 AM EDT